TYPE 2 DIABETES MELLITUS AS A DETERMINANT OF CARDIOVASCULAR COMPLICATIONS DEVELOPMENT
Keywords:
Type 2 diabetes mellitus; cardiovascular complications; atherosclerosis; endothelial dysfunction; insulin resistance; cardiovascular risk.Abstract
Type 2 diabetes mellitus represents a major global public health challenge and is strongly associated with an increased risk of cardiovascular morbidity and mortality. The present study aims to analyze type 2 diabetes mellitus as a key pathogenic factor contributing to the development of cardiovascular complications. The research is based on the analysis of clinical, metabolic, and epidemiological data reflecting the impact of chronic hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation on the cardiovascular system. Particular attention is given to the mechanisms linking diabetes with atherosclerosis progression, endothelial dysfunction, arterial stiffness, and myocardial structural remodeling. The results indicate that type 2 diabetes mellitus significantly accelerates the development of ischemic heart disease, hypertension, heart failure, and cerebrovascular disorders, even in the absence of overt clinical symptoms at early stages. The findings emphasize that cardiovascular complications often develop subclinically and progress more aggressively in patients with type 2 diabetes. These observations highlight the necessity of early identification of cardiovascular risk factors, comprehensive metabolic control, and integrated preventive strategies aimed at reducing cardiovascular burden in patients with type 2 diabetes mellitus.
References
1.American Diabetes Association. (2023). Cardiovascular disease and risk management: Standards of care in diabetes—2023. Diabetes Care, 46(Supplement 1), S158–S190. https://doi.org/10.2337/dc23-S010
2.Cosentino, F., Grant, P. J., Aboyans, V., et al. (2020). 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal, 41(2), 255–323. https://doi.org/10.1093/eurheartj/ehz486
3.Fox, C. S., Golden, S. H., Anderson, C., et al. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus. Circulation, 132(8), 691–718. https://doi.org/10.1161/CIR.0000000000000230
4.Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes. New England Journal of Medicine, 339(4), 229–234. https://doi.org/10.1056/NEJM199807233390404
5.Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016). Clinical update: Cardiovascular disease in diabetes mellitus. Circulation, 133(24), 2459–2502. https://doi.org/10.1161/CIRCULATIONAHA.116.022194
6.Rawshani, A., Rawshani, A., Franzén, S., et al. (2018). Mortality and cardiovascular disease in type 2 diabetes. New England Journal of Medicine, 379(7), 633–644. https://doi.org/10.1056/NEJMoa1800256
7.Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. Фтизиатрия и пульмонология, (2), 136-136.
8.Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. Новый день в медицине, (1), 48-51.
9.Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10.Ташпулатова, Ф. К., Галиулин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. Интернаука, (14-1), 52-53.
